The Risk of Ovarian Malignancy Algorithm (ROMA) algorithm was approved by the FDA in 2011. Research demonstrates that examining levels of HE4 and CA125 using the ROMA algorithm shows the highest accuracy in determining ovarian cancer risk in pre- and post-menopausal women who have an ovarian mass present.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
The risk of malignancy algorithm (ROMA) includes CA125, human epididymal protein 4 (HE4) and menopausal status, but not imaging results.